Allergan's most recent trend suggests a bullish bias. One trading opportunity on Allergan is a Bull Put Spread using a strike $170.00 short put and a strike $160.00 long put offers a potential 16.96% return on risk over the next 28 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $170.00 by expiration. The full premium credit of $1.45 would be kept by the premium seller. The risk of $8.55 would be incurred if the stock dropped below the $160.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Allergan is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Allergan is bullish.
The RSI indicator is at 70.87 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
Allergan Needs More Time to Make a Proper Bottom
Wed, 17 Jan 2018 19:53:00 +0000
The charts suggest that Allergan isn't going to accelerate any time soon.
Polaris Global Value Fund 4th Quarter Shareholder Letter
Wed, 17 Jan 2018 16:59:23 +0000
Review of markets and holdings
Judge approves settlement between Allergan shareholders and Ackman
Wed, 17 Jan 2018 15:49:37 +0000
Bill Ackman’s $290 million settlement agreement with shareholders of drug developer Allergan plc has the support of a California federal judge. This is good news for the New York-based activist investor and Valeant Pharmaceuticals, as the two parties are being sued for insider trading. “The Court has vacated the trial date and indicated its preliminary approval of the settlement subject to submission of final papers and associated hearings,” Valeant said in a statement.
[$$] Judge Signals He Will Approve $290 Million Settlement Between Allergan Shareholders and Pershing, Valeant
Wed, 17 Jan 2018 05:14:11 +0000
A federal judge signaled he would approve a $290 million settlement reached by Pershing Square, Valeant and the shareholders of Allergan who had alleged the two firms improperly profited from their failed …
Imprimis receives FDA warning over eye medication advertising
Tue, 16 Jan 2018 21:59:39 +0000
The U.S. Food and Drug Administration has issued a warning letter to Imprimis Pharmaceuticals Inc accusing it of making false or misleading claims that its compounded eye medications had the agency's approval. The Dec. 21 letter to San Diego-based Imprimis was posted on the FDA's website on Tuesday. Imprimis is contesting a lawsuit by rival Allergan Plc over allegations it is illegally selling and advertising unapproved drugs.
Also on Market Tamer…
Follow Us on Facebook